Press Releases

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the...

Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and...

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is...

Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section...

Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is...

On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The...

Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of...

Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its...

Infant Bacterial Therapeutics ABs CFO Marie Louise Alamaa left the company to pursue new opportunities. IBT’s Controller, Michael Owens, has assumed the responsibility of CFO moving forward. “I...

A blinded evaluation of IBT’s Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology® on December 6, 2021. The evaluation reveals...

Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"),...

Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the AGM, which is planned to be held on May 4, 2022. The Nomination Committee is composed, according to...

Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing Clinical Phase III study of IBP-9414....

After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce...

Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico Infant Bacterial Therapeutics AB today announces that the Mexican Patent Office has granted a patent entitled: A...

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol...

Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development program with our drug candidate IBP-9414,...

Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August 16, 2021. She will be part of the Management...

Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be...

CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics ABInfant Bacterial Therapeutics AB (publ) is a...

Message from the CEO IBT is conducting a phase III-study (“The Connection Study”) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414...

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: adoption of the annual reportthat no dividend is...

After the Data Monitoring Committees’ review Infant Bacterial Therapeutics expands the enrollment criteria of The Connection Study to include 500 - 1000 gram birth weight premature infants....

Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid...

Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2020. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media...

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, May 4, 2021. In light of the coronavirus, the Annual General Meeting is conducted...

Infant Bacterial Therapeutics (IBT) announces that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP-9414. This in...

Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the...

Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....

The Annual General Meeting of 2020 decided that the Nomination Committee would be appointed as follows: “The Chairman of the Board shall convene the three largest shareholders in the Company, who...

Message from the CEO   IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in...

Message from the CEO   IBT is currently developing its drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so called “feeding tolerance” in...

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on June 16, 2020, among other things, the following was resolved:   adoption of the annual report discharge...

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, June 16, 2020. In light of the coronavirus, the Annual General Meeting is...

Message from the CEO   IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so called “feeding intolerance”...

Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2019.   The report is available on IBT’s website ibtherapeutics.com under the section...

Due to the difficulty of gathering in larger groups, caused by the Corona Epidemic, IBT's Board of Directors has decided to postpone the Annual General Meeting until June 16, 2020, instead...

Message from the CEO   IBT’s ongoing clinical phase III study with IBP-9414 has, as of the date of this year-end report, conducted patient recruitment for more than seven months....

The Annual General Meeting of 2019 decided that the Nomination Committee would be appointed as follows: “The Chairman of the Board shall convene the three largest shareholders in the...

Message from the CEO   In our previous quarterly report we were able to announce that the first patient had been recruited in our clinical phase III-study. This study is...

Lilian Wikström Ph.D. has requested to resign from the Board of Directors of IBT with immediate effect due to the risk of conflict of interest that has arisen in her role as CEO of KI...

Message from the CEO   On July 4 we were able to announce that the first patient had been recruited and dosed in the company’s clinical phase III-study. Our work is now focused on...

IBT has recruited the first patient in the Phase III pivotal clinical study, The Connection Study. The development program for IBP-9414, of which The Connection Study is the final planned...

IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on how the company's planned Phase III study should be designed. The FDA has now informed IBT in writing...

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 6, 2019, among other things, the following was resolved:   determination of the annual report discharge...

Message from the CEO   As previously communicated, IBT had a meeting with the Food and Drug Administration (FDA) on November 20, 2018, to discuss IBT’s clinical development program. The...

Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Monday, May 6, 2019 at 15.00 at Svenska Läkaresällskapet på Klara Östra Kyrkogata 10 i...

Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2018.   The report is available on IBT’s website ibtherapeutics.com under the...

Infant Bacterial Therapeutics AB has today signed the first distribution agreement for IBP-9414 with Megapharm Ltd. for the Israeli market and the Palestinian Authority’s territories. The...

Message from the CEO   IBT reached several significant milestones during 2018. IBT reached agreement with a CRO (Contract Research Organization) to conduct the pivotal Phase III...

Yesterday afternoon (EST) Infant Bacterial Therapeutics  had a meeting with the US Food and Drug Administration (FDA) in Washington DC to discuss the design of the company's clinical...

Message from the CEO   The third quarter was dominated by extensive preparatory work relating to the planned phase III study, called “The Connection Study”. In addition to chosing...

The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the...

Message from the CEO   The second quarter was dominated by extensive preparatory work relating to the pivotal phase III study, called “The Connection Study”. Our experience from...

The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 15, 2018 voted to approve the following resolutions:   Adoption of the annual report Discharge...

Message from the CEO   During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent...

The IBT Nomination Committee presented its proposals to the AGM in April 2018, which will be held on May 15, 2018.   The Nomination Committee has subsequently been informed that...

Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Tuesday, May 15, 2018 at 15.00 in the City Conference Ingenjörshuset, Malmskillnadsgatan 46,...

Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2017. The report is available on IBT’s website under the section Financial Reports...

Message from the CEO  During the last year, IBT passed the most important milestones in the company’s history. The company’s pharmaceutical candidate, IBP-9414, for the prevention of...

To access the press release, please read the following disclaimer here.

To access the press release, please read the following disclaimer here.

The extraordinary general meeting of Infant Bacterial Therapeutics AB (publ) (“IBT”) on 8 January 2018 resolved, among other things, to approve the board of directors’ resolution of...

Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu presented data today from its Safety and Tolerability study in premature infants at the ongoing Hot Topics in...

The shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to an extraordinary general meeting on Monday 8 January 2018 at 10.00 am at Citykonferensen Ingenjörshuset,...

Read more here.

Message from the CEO IBT announced results from the safety and tolerability study of IBP-9414 on September 11th. The data demonstrate a similar safety and tolerability profile in the active...

The Annual General Meeting of 2017 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the...

The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) proposed by IBT for the development of...

Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II “Randomized, double blind, parallel-group,...

Message from the CEO   IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations for a subsequent...

The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2017 voted to approve the following resolutions:   Adoption of the annual report Discharge from...

Message from the CEO IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following clinical Phase lll study of IBP-9414. As...

Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the companies website www.ibtherapeutics.com.   A physical copy of the Annual Report can also be...

Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on Thursday, 4 May 2017, at Citykonferensen Ingenjörshuset, Malmskillnadsgatan 46,...

Infant Bacterial Therapeutics AB (publ) (“IBT”), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First North’s Premier segment. Companies which are...

Message from the CEO “During the month of June, the first patients were recruited and dosed in IBTs clinical study, IBP-9414, in the USA.  The last patient was recruited on January 23, 2017...

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed.   The Phase 2 study...

Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, is in the early planning stages of developing a...

IBT announces that the second and last planned evaluation of safety data by the independent Data Safety Monitoring Board (DSMB), in the ongoing Phase II clinical study, was performed on...

Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role....

Message from the CEO “In June we announced that the first premature infant had been enrolled and dosed in the Company´s Phase ll clinical trial. This Phase ll trial is a randomized,...

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a...

The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) rights issue, for which the subscription period ended on 23 May 2016, indicates that 3,575,583 shares,...

To access the press release, please read the following disclaimer here.

To access the press release, please read the following disclaimer here.

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the U.S. Food and Drug Administration (FDA) has awarded IBT Rare Pediatric Disease Designation for its drug candidate IBP-9414,...

Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser...

The board of directors of parent company BioGaia AB (publ) has resolved to propose to an Extraordinary General Meeting in BioGaia on 18 March 2016 to distribute the shares in the subsidiary Infant...

IBT announces today that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by the FDA (U.S. Food and Drug Administration). Furthermore, IBT...

Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520...

Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus reuteri for the prevention of necrotizing enterocolitis in Europe. Read the official press release here

Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request. Read the official press...

The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly...